Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio.
NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...
Vertex Earnings: Robust Sales of Trikafta/Kaftrio Support Long-Term Growth and Diverse Pipeline Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product ...
More than 30,0000 additional patients worldwide who are currently untreated will be able to seek treatment using Vertex’s recently approved triple combination regimen, Trikafta/Kaftrio.
The company’s 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification ...
Hosted on MSN1mon
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesTotal revenues rose 16% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). The company currently markets four CF products, Trikafta/Kaftrio ...
Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of its blockbuster CF medicine, Trikafta/Kaftrio (Trikafta’s brand name in Europe), in younger age groups.
But when she found out about the drug Trikafta, she started thinking, “we can manage this”. Cystic fibrosis is a condition that produces thick and sticky mucus and mainly affects the lungs and ...
Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Kaftrio as a combination therapy for CF patients aged two years and older with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results